

8. How sure are we about the results? Consequences and cost of alternatives performed?	GP		MED	MED	MED	HIG	HIG	HIG	HIG	HIG	HIG	LOW	LOW	LOW	MED	LOW	MED	HIG	LOW	LOW	HIG
	LE		MED	MED	MED	HIG	HIG	HIG	HIG	HIG	HIG	LOW	LOW	LOW	MED	LOW	MED	HIG	LOW	LOW	HIG
	AG																				
9. Can the results be applied to your patients/ the population of interest?	GP		CT	CT	CT	CT	CT	CT	CT	CT	CT	CT	CT	CT	Y	Y	CT	CT	CT	CT	CT
	LE		Y	Y	Y	Y	Y	Y	Y	Y	Y	CT	CT	CT	Y	CT	CT	Y	Y	CT	CT
	AG		Y	Y	Y	Y	Y	Y	Y	Y	Y					CT		Y	Y		
10. Can the test be applied to your patient or population of interest?	GP		N	CT	CT	CT	CT	CT	CT	CT	CT	CT	CT	CT	Y	Y	CT	CT	CT	CT	CT
	LE		Y	Y	Y	Y	Y	Y	Y	Y	Y	CT	CT	CT	Y	CT	CT	Y	Y	CT	CT
	AG		Y	Y	Y	Y	Y	Y	Y	Y	Y					CT		Y	Y		
11. Were all outcomes important to the individual or population considered?	GP		CT	Y	Y	CT	Y	Y	CT	Y	CT	CT	Y	Y	Y	Y	Y	Y	CT	Y	N
	LE		CT	CT	Y	CT	Y	Y	CT	Y	CT	CT	CT	CT	Y	CT	Y	Y	CT	CT	N
	AG			CT									CT	CT		CT				CT	
12. What would be the impact of using this test on your patients/population?	GP		DK	DK	DK	DK	DK	HIG	DK	HIG	HIG	DK	DK	DK	DK	CLD	CLD	CLD	DK	CLD	DK
	LE		CLD	DK	DK	DK	CLD	HIG	DK	HIG	HIG	DK	DK	DK	DK	CLD	CLD	CLD	DK	CLD	DK
	AG		CLD				CLD														

GP: Giulia Poletto; LE: Laura Evangelista; AG: agree; Y: yes; N: No, CT: can't tell; CLR: clear; NCLR: not clear; MED: medium; HIG: high; DK: don't know; CLD: it could

Table S2. Change of management with PET imaging in patients affected by neuroendocrine tumor

Authors, ref	Number of patients with change/total study population	% of change management
Buchmann et al	1/27	3.7%
Srirajaskanthan et al,	36/51	70.6%
Gabriel et al (2007),	12/84	14.3%
Madrzak et al,	2/24	8.4%
Krausz et al,	3/19	15.8%